NASDAQ$OFIX
Orthofix Medical Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Orthofix's second quarter results reflected double-digit growth in global orthopedics and progress in innovation initiatives, offset by macro headwinds and currency fluctuations.
Orthofix reported Q2 2022 net sales of $118.1 million, a decrease of 3% on a reported basis but flat on a constant currency basis. GAAP EPS was $0.12, and adjusted EPS was $0.08. The company is maintaining full-year revenue guidance of $455 to $465 million.
- Net sales decreased by 3% on a reported basis but were flat on a constant currency basis compared to the prior year.
- Global Orthopedics net sales grew by 11% on a constant currency basis, driven by new products and channel investments.
- GAAP EPS was $0.12, and adjusted EPS was $0.08.
- The company executed a partnership with CGBio to commercialize Novosis™ rhBMP-2 growth factor in the U.S. and Canada.
Headline financials
Revenue & EPS history
Orthofix · Revenue · Quarterly
$118M
Revenue by segment
Orthofix · $103M total across 3 segments · Q2 2022
- Bone Growth Therapies$47.8M-3.9%46.3%
- Spinal Implants & Biologics$28.2M-6.2%27.3%
- Global Limb Reconstruction$27.3M+2.0%26.4%
Forward guidance
The Company expects full year net sales to be in the range of $455 to $465 million, representing flat to 2% growth on a constant currency basis. Full year adjusted EBITDA is expected to be $53 to $57 million, and adjusted EPS is expected to be $0.45 to $0.55.
Tailwinds
- Full year net sales growth rates – constant currency 0% - 2%
- Full year adjusted EBITDA $53 - $57
- Full year adjusted EBITDA as percentage of net sales 12%
- Full year adjusted EPS $0.45-$0.55
Headwinds
- Full year net sales $455 - $465
- Full year net sales growth rates – reported (2%) - 0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
-0.9%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-3.4%
Avg return
30 days after
48%
31 / 65 earnings
Positive
+20.3%
Q2 2014
Best reaction
-18.5%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | -2.8% | -13.8% | |
| Q4 2025 | -7.0% | -0.4% | -13.2% | |
| Q3 2025 | -7.4% | -6.8% | -1.0% | |
| Q1 2025 | -10.8% | -10.6% | -20.9% | |
| Q4 2024 | -3.5% | -4.2% | -11.0% | |
| Q3 2024 | +5.5% | +4.6% | +1.2% | |
| Q2 2024 | +13.8% | +10.8% | +16.7% | |
| Q1 2024 | +10.7% | +8.8% | +0.6% | |
| Q4 2023 | +8.1% | +7.1% | +8.6% | |
| Q3 2023 | -12.5% | -20.2% | -3.2% | |
| Q2 2023 | +9.9% | +7.6% | +1.3% | |
| Q1 2023 | +1.0% | -2.3% | +6.7% | |
| Q4 2022 | -7.7% | -13.2% | -15.5% | |
| Q3 2022 | -2.2% | +4.1% | +30.5% | |
| Q2 2022 | -6.6% | -8.8% | -20.9% | |
| Q1 2022 | -10.5% | -14.3% | -11.6% | |
| Q4 2021 | +4.0% | +3.5% | +0.4% | |
| Q3 2021 | -5.9% | -10.9% | -18.6% | |
| Q2 2021 | +8.9% | +4.1% | +12.4% | |
| Q1 2021 | +0.5% | -2.0% | -8.7% | |
| Q4 2020 | +0.6% | -0.5% | -7.3% | |
| Q3 2020 | +5.2% | +13.6% | +10.8% | |
| Q2 2020 | +4.5% | +4.6% | -13.4% | |
| Q1 2020 | -1.9% | -6.9% | +3.9% | |
| Q4 2019 | -18.5% | -21.5% | -40.9% | |
| Q3 2019 | -16.8% | -17.0% | -9.6% | |
| Q2 2019 | +0.1% | +2.6% | -5.5% | |
| Q1 2019 | -2.6% | -0.3% | -10.9% | |
| Q4 2018 | -8.5% | -10.0% | -14.8% | |
| Q3 2018 | +7.4% | +8.8% | +4.1% | |
| Q2 2018 | -15.1% | -11.9% | -12.1% | |
| Q1 2018 | -13.4% | -14.6% | -10.5% | |
| Q4 2017 | +6.4% | +4.6% | +8.4% | |
| Q3 2017 | +8.8% | +5.1% | +9.6% | |
| Q2 2017 | +9.9% | +6.8% | +12.3% | |
| Q1 2017 | +1.4% | +3.8% | +8.2% | |
| Q4 2016 | -6.1% | -4.8% | +2.6% | |
| Q3 2016 | -3.8% | -6.8% | -1.5% | |
| Q2 2016 | -10.4% | -10.5% | -4.8% | |
| Q1 2016 | +0.4% | — | — | |
| Q4 2015 | +2.8% | — | — | |
| Q3 2015 | +14.4% | — | — | |
| Q2 2015 | +13.8% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | -10.8% | — | — | |
| Q3 2014 | +20.3% | — | — | |
| Q2 2014 | +20.3% | — | — | |
| Q1 2014 | +4.2% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | +1.1% | — | — | |
| Q2 2013 | -0.8% | — | — | |
| Q1 2013 | -16.4% | — | — | |
| Q4 2012 | -4.9% | — | — | |
| Q3 2012 | -2.8% | — | — | |
| Q2 2012 | +4.5% | — | — | |
| Q1 2011 | -0.7% | — | — | |
| Q1 2012 | +1.0% | — | — | |
| Q1 2010 | -4.8% | — | — | |
| Q4 2011 | -4.8% | — | — | |
| Q4 2009 | -4.8% | — | — | |
| Q3 2010 | -7.4% | — | — | |
| Q3 2011 | -7.4% | — | — | |
| Q4 2010 | -9.5% | — | — | |
| Q2 2010 | -9.5% | — | — | |
| Q2 2011 | -9.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro